PubHawk
November 2006 PMID 17108343

Correction of anemia with epoetin alfa in chronic kidney disease.

Ajay K Singh, Lynda Szczech, Kezhen L Tang, Huiman Barnhart, Shelly Sapp, Marsha Wolfson, Donal Reddan

Full text PDF Download social card

Mentions

49
Peak: 8 in Mar 2024
across 4 sources since Jan 2019

Extended reach

141,597
potential audience

Total likes

401

Video views

13,856

Mentions per month

Jan 2019 – Aug 2025

Where it's discussed

  • X / Twitter33 posts
  • Blogs8 articles
  • News5 articles
  • YouTube3 videos

AI synopsis

What people are saying

Many discussions highlight the significance of the study's findings, with posts referencing data such as increased cardiovascular events at higher hemoglobin levels, and contemplating clinical implications by labeling this research as 'game-changing.' The tone ranges from analytical to inquisitive, emphasizing the importance of precise anemia management in chronic kidney disease and indicating a recognition of its potential to shape future treatment protocols.

AgreementModerate agreement

Several discussions acknowledge the research's findings that higher hemoglobin targets may lead to increased health risks, reflecting support and acceptance of the study's conclusions.

InterestHigh interest

Many posts show strong curiosity, referencing detailed trial results and engaging with treatment debates, indicating a high level of interest.

EngagementHigh engagement

Posts frequently analyze implications, cite specific data like adverse event rates, and discuss treatment standards, demonstrating deep engagement.

ImpactModerate impact

The discussions suggest the publication influences current treatment considerations and encourages further debate, indicating a moderate perception of high impact.

Abstract in brief

  • Anemia is a common issue in chronic kidney disease due to a lack of erythropoietin, and this study explores the effects of targeting different hemoglobin levels with epoetin alfa.
  • In a trial with 1432 patients, those aiming for a hemoglobin of 13.5 g/dL faced more adverse events, with a total of 222 combined serious outcomes compared to 97 in the lower target group of 11.3 g/dL.
  • Findings suggest that a higher target hemoglobin level does not improve quality of life and is linked to greater health risks, indicating a need for careful management of anemia in kidney disease.
Read the full abstract

Top posts

Most liked on X and Bluesky
長澤　将（腎臓内科医）
@RealTNagasawa · X

これは13g/dlを超えると、心血管合併症のリスクをあげるためです。https://t.co/69tsko0sCY

Apr 28, 2021 · 21 likes · 5,204 followers View post →
NDT
@NDTsocial · X

NDT on MARKUS@HOMe! Iain Macdougall presents the current treatment standards for renal anemia His NDT paper ‘Anemia in CKD - treatment standard’ has been picked by the MARKUS @ HOMe editors as ‘NDT's Paper of the Month’!

Mar 11, 2024 · 18 likes · 3 shares · 18,097 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Here comey our next "Best of NDT" pick: Treatment of Renal Anaemia with Prof. Dr. Iain Macdougall With @NDTsocial @AKronbichler @hjanders_hans @oegnephro @com_SFNDT @dgfn_ev Available from 7:15 PM CET 6:15 PM GMT https://t.co/eDaKVmGwC6 via @YouTube

Mar 8, 2024 · 11 likes · 2 shares · 2,325 followers View post →
Landmark Trials
@LandmarkTrials · X

Why target a Hb of 11.0 for patients with anemia of CKD requiring epoetin alfa? The CHOIR trial has some answers! See more: https://t.co/bAJjR9OGED Original study: https://t.co/jYtqDsv5oW #EBM #MedEd #MedStudentTwitter #Nephrology #hematology #MedTwitter #research https://t.co/DAJuyFkj1o

Oct 25, 2022 · 11 likes · 2 shares · 850 followers View post →
NefroClass
@NefroClassMx · X

Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ Mortalidad ☠️ (9.2% vs 5.0%; p=0.01) Sin mejora en calidad de vida

Apr 18, 2025 · 9 likes · 6 shares · 7,672 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Will "Fantastic 4" in Heart Failure today become "Fantastic 5", adding iv iron to ACE-I or Sacubitril/AT-1-A, MRA, SGLT-2 and BB? While waiting for IRONMAN to be presented at #AHA2022 tonight, enjoy our discussion with @ArdehaliHossein and Prof. Macdougall https://t.co/fm59v374xf

Nov 5, 2022 · 6 likes · 2,325 followers View post →

All mentions

José Mª Gª Quintana
@jose_g_quintana · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 19, 2025 · 6 shares · 846 followers View post →
Marco MF
@MarcoMF7 · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 19, 2025 · 6 shares · 80 followers View post →
Salvador QH.
@Destro3yr · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 18, 2025 · 6 shares · 272 followers View post →
diacavan
@diacavan · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 18, 2025 · 6 shares · 165 followers View post →
Dr. Ronald Caraballo NEFROLOGO
@ronald_nefro · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 18, 2025 · 6 shares · 663 followers View post →
Avel con V chica
@AvelRomanNeph · X

RT @NefroClassMx: Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ M…

Apr 18, 2025 · 6 shares · 2,934 followers View post →
NefroClass
@NefroClassMx · X

Menos es más? Subir Hb a 13.5 g/dL en ERC? ⚠️ Más eventos CV ❤️ (17.5% vs 13.6%) HR 1.34 (IC 95%: 1.03–1.74; p=0.03) ↑ Mortalidad ☠️ (9.2% vs 5.0%; p=0.01) Sin mejora en calidad de vida

Apr 18, 2025 · 9 likes · 6 shares · 7,672 followers View post →
Ankur Gupta
@ankurparth · X

Correct or not to correct

Nov 16, 2024 · 619 followers View post →
Mayra Avilés
@marsdance21 · X

RT @NDTsocial: NDT on MARKUS@HOMe! Iain Macdougall presents the current treatment standards for renal anemia His NDT paper ‘Anemia in CKD…

Mar 12, 2024 · 3 shares · 291 followers View post →
Hans-Joachim Anders
@hjanders_hans · X

RT @NDTsocial: NDT on MARKUS@HOMe! Iain Macdougall presents the current treatment standards for renal anemia His NDT paper ‘Anemia in CKD…

Mar 11, 2024 · 3 shares · 2,938 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

RT @NDTsocial: NDT on MARKUS@HOMe! Iain Macdougall presents the current treatment standards for renal anemia His NDT paper ‘Anemia in CKD…

Mar 11, 2024 · 3 shares · 2,325 followers View post →
NDT
@NDTsocial · X

NDT on MARKUS@HOMe! Iain Macdougall presents the current treatment standards for renal anemia His NDT paper ‘Anemia in CKD - treatment standard’ has been picked by the MARKUS @ HOMe editors as ‘NDT's Paper of the Month’!

Mar 11, 2024 · 18 likes · 3 shares · 18,097 followers View post →
Reny Duarsa
@Renaladdict · X

RT @gunnar_heine: Here comey our next "Best of NDT" pick: Treatment of Renal Anaemia with Prof. Dr. Iain Macdougall With @NDTsocial @AKro…

Mar 8, 2024 · 2 shares · 504 followers View post →
Hans-Joachim Anders
@hjanders_hans · X

RT @gunnar_heine: Here comey our next "Best of NDT" pick: Treatment of Renal Anaemia with Prof. Dr. Iain Macdougall With @NDTsocial @AKro…

Mar 8, 2024 · 2 shares · 2,938 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Here comey our next "Best of NDT" pick: Treatment of Renal Anaemia with Prof. Dr. Iain Macdougall With @NDTsocial @AKronbichler @hjanders_hans @oegnephro @com_SFNDT @dgfn_ev Available from 7:15 PM CET 6:15 PM GMT https://t.co/eDaKVmGwC6 via @YouTube

Mar 8, 2024 · 11 likes · 2 shares · 2,325 followers View post →
Raza S
@RazaSN · X

Erythropoetin Agonists/Synthetics ↑Red cell production such as in CKD Arterial thrombosis in trials Mechanism: ↑CRP, nitric oxide, TAFI → fibrinolytic deficit Nuances: clotting data only for chronic use; mainly at Hb>110 https://t.co/UGgtZfDiLi https://t.co/ZzZxUzgQfX https://t.co/ooMgIUPqhw

Apr 4, 2023 · 420 followers View post →
Mbali
@e_daisyjackson7 · X

https://t.co/CyBQLmjDVi

Feb 21, 2023 · 1,434 followers View post →
Pablo Angeles Tacchino
@pabloange · X

RT @LandmarkTrials: Why target a Hb of 11.0 for patients with anemia of CKD requiring epoetin alfa? The CHOIR trial has some answers! See…

Dec 4, 2022 · 2 shares · 754 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Will "Fantastic 4" in Heart Failure today become "Fantastic 5", adding iv iron to ACE-I or Sacubitril/AT-1-A, MRA, SGLT-2 and BB? While waiting for IRONMAN to be presented at #AHA2022 tonight, enjoy our discussion with @ArdehaliHossein and Prof. Macdougall https://t.co/fm59v374xf

Nov 5, 2022 · 6 likes · 2,325 followers View post →
Amr Nagy
@amronagyMD · X

RT @LandmarkTrials: Why target a Hb of 11.0 for patients with anemia of CKD requiring epoetin alfa? The CHOIR trial has some answers! See…

Oct 25, 2022 · 2 shares · 388 followers View post →
Landmark Trials
@LandmarkTrials · X

Why target a Hb of 11.0 for patients with anemia of CKD requiring epoetin alfa? The CHOIR trial has some answers! See more: https://t.co/bAJjR9OGED Original study: https://t.co/jYtqDsv5oW #EBM #MedEd #MedStudentTwitter #Nephrology #hematology #MedTwitter #research https://t.co/DAJuyFkj1o

Oct 25, 2022 · 11 likes · 2 shares · 850 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

@luisbeckdasilva @FabiMarcondesB @LidiaMoura17 @pedschwartzmann Thanks, Dr Beck da Silva! Here comes our contribution https://t.co/fm59v36wHH

Sep 25, 2022 · 2,325 followers View post →
Stephan Schirmer
@StephanSchirme2 · X

RT @gunnar_heine: The IRON debate before the IRONMAN study presentation at AHA 2022 with Prof Macdougall and @ArdehaliHossein https://t.co…

Sep 23, 2022 · 1 share · 8 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

The IRON debate before the IRONMAN study presentation at AHA 2022 with Prof Macdougall and @ArdehaliHossein https://t.co/fm59v374xf via @YouTube @oegnephro @com_SFNDT @oegnephro @StephanSchirme1

Sep 23, 2022 · 5 likes · 1 share · 2,325 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

@ArdehaliHossein @NMSurgery @NMHospMed Best wishes to both of you - and enjoy tonight by watching our debate on YouTube on iv iron https://t.co/fm59v374xf (at 1:30 East Coast, 12:30 Chicago). Have a peaceful week-end!

Sep 23, 2022 · 1 like · 2,325 followers View post →
KIReports
@KIReports · X

CHOIR (c. 2006) 1432 CKD patients.

Oct 19, 2021 · 3 likes · 13,537 followers View post →
Catherine Clase
@CMClase · X

@askrenal @NephJC @thisis_drgsp @hswapnil @arvindcanchi @GlassockJ Quite unlikely Choir https://t.co/KXpNy7usJv https://t.co/pSpnY6Polz

Sep 26, 2021 · 2 likes · 2,017 followers View post →
長澤　将（腎臓内科医）
@RealTNagasawa · X

これは13g/dlを超えると、心血管合併症のリスクをあげるためです。https://t.co/69tsko0sCY

Apr 28, 2021 · 21 likes · 5,204 followers View post →
Nephrology Journal Club
@NephJC · X

T0: Let’s take a look at the CHOIR Trial

Feb 24, 2021 · 2 likes · 38,240 followers View post →
FOAM Cards
@FOAM_Cards · X

(1/2)Trial of the day: CHOIR Singh, AK et al. "Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease". The New England Journal of Medicine. 2006. 355(20):2085-2098. https://t.co/i5gg27LzzO #FOAMcards

Feb 26, 2019 · 68 followers View post →
Dr Theepa N.M.R
@TNesam · X

RT @nephondemand: • CHOIR https://t.co/hKLqsCKZ8P Randomized non-placebo trial of Epoetin in CKD 3-4 patients to achieve a Hemoglobin of 11…

Jan 27, 2019 · 4 shares · 698 followers View post →
madree
@madrees007 · X

RT @nephondemand: • CHOIR https://t.co/hKLqsCKZ8P Randomized non-placebo trial of Epoetin in CKD 3-4 patients to achieve a Hemoglobin of 11…

Jan 21, 2019 · 4 shares · 53 followers View post →
Tejas Desai, MD, MBA
@nephondemand · X

• CHOIR https://t.co/hKLqsCKZ8P Randomized non-placebo trial of Epoetin in CKD 3-4 patients to achieve a Hemoglobin of 11.0 -11.5 vs ~ 13 g/dl. Worse cardiovascular outcomes in the latter group. #meded #FOAMed https://t.co/ip8SaHDrtx

Jan 16, 2019 · 5 likes · 4 shares · 11,942 followers View post →